keyword
MENU ▼
Read by QxMD icon Read
search

Buprenorphine and adherence

keyword
https://www.readbyqxmd.com/read/29450210/sofosbuvir-based-direct-acting-antiviral-therapies-for-hcv-in-people-receiving-opioid-substitution-therapy-an-analysis-of-phase-3-studies
#1
Jason Grebely, Jordan J Feld, David Wyles, Mark Sulkowski, Liyun Ni, Joe Llewellyn, Heshaam M Mir, Nika Sajed, Luisa M Stamm, Robert H Hyland, John McNally, Diana M Brainard, Ira Jacobson, Stefan Zeuzem, Marc Bourlière, Graham Foster, Nezam Afdhal, Gregory J Dore
Background: Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The aim of this study was to evaluate the treatment completion, adherence, SVR12, and safety of sofosbuvir-based therapies in HCV patients receiving and not receiving OST. Methods: Ten phase 3 studies of sofosbuvir-based regimens included ION (ledipasvir/sofosbuvir ± ribavirin for 8, 12, or 24 weeks in GT1), ASTRAL (sofosbuvir/velpatasvir for 12 weeks in GT1-6), and POLARIS (sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir in GT1-6)...
February 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29432333/buprenorphine-treatment-for-adolescents-and-young-adults-with-opioid-use-disorders-a-narrative-review
#2
Jacob T Borodovsky, Sharon Levy, Marc Fishman, Lisa A Marsch
: In the past decade, a new cohort of adolescents and young adults with opioid use disorders (OUD) has emerged. While medications and psychosocial treatments are available, few adolescents and young adults with OUD can access and remain in treatment. Effective, practical, and scalable treatment paradigms for this young population are needed. Buprenorphine is a medication with unique pharmacological and regulatory characteristics that make it a promising component of adolescent and young adult OUD treatment models...
February 9, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29426304/rationale-design-and-methodology-of-a-trial-evaluating-three-models-of-care-for-hcv-treatment-among-injection-drug-users-on-opioid-agonist-therapy
#3
Matthew J Akiyama, Linda Agyemang, Julia H Arnsten, Moonseong Heo, Brianna L Norton, Bruce R Schackman, Benjamin P Linas, Alain H Litwin
BACKGROUND: People who inject drugs (PWID) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). Treatment of PWID is complex due to addiction, mental illness, poverty, homelessness, lack of positive social support, poor adherence-related skills, low motivation and knowledge, and poor access to and trust in the health care system. New direct-acting antiviral medications are available for HCV with high cure rates and few side effects. The life expectancy and economic benefits of new HCV treatments will not be realized unless we determine optimal models of care for the majority of HCV-infected patients...
February 9, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29415846/associations-between-pharmacotherapy-for-opioid-dependence-and-clinical-and-criminal-justice-outcomes-among-adults-with-co-occurring-serious-mental-illness
#4
Allison G Robertson, Michele M Easter, Hsiu-Ju Lin, Linda K Frisman, Jeffrey W Swanson, Marvin S Swartz
Adults suffering from a serious mental illness (SMI) and a substance use disorder are at especially high risk for poor clinical outcomes and also arrest and incarceration. Pharmacotherapies for treating opioid dependence could be a particularly important mode of treatment for opioid-dependent adults with SMI to lower their risk for overdose, high-cost hospitalizations, repeated emergency department visits, and incarceration, given relapse rates are very high following detoxification in the absence of one of the three FDA-approved pharmacotherapies...
March 2018: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/29396985/extended-release-injectable-naltrexone-for-opioid-use-disorder-a-systematic-review
#5
REVIEW
Brantley P Jarvis, August F Holtyn, Shrinidhi Subramaniam, D Andrew Tompkins, Emmanuel A Oga, George E Bigelow, Kenneth Silverman
AIMS: To review systematically the published literature on extended-release naltrexone (XR-NTX, Vivitrol®), marketed as a once-per-month injection product to treat opioid use disorder. We addressed the following questions: (1) How successful is induction on XR-NTX?; (2) What are adherence rates to XR-NTX?; and (3) Does XR-NTX decrease opioid use? Factors associated with these outcomes as well as overdose rates were examined. METHODS: We searched PubMed and used Google Scholar for forward citation searches of peer-reviewed articles from January 2006 to June 2017...
February 3, 2018: Addiction
https://www.readbyqxmd.com/read/29320915/healthcare-utilization-and-costs-associated-with-treatment-for-opioid-dependence
#6
Ankit Shah, Margaret Duncan, Nipun Atreja, Kei Sing Tai, Mugdha Gore
OBJECTIVE: Opioid use disorder (OUD) can be managed with medication assisted therapy (MAT) (methadone [MET], buprenorphine [BUP], or extended-release naltrexone [XR-NTX]) or counseling alone (non-pharmacological therapy [NPT]). The objective of this study was to evaluate healthcare resource utilization and costs associated with XR-NTX compared with alternative treatments for opioid dependence. METHODS: Adults with a diagnosis of opioid dependence who initiated treatment with XR-NTX, BUP, MET, or NPT between January 1, 2011 and December 31, 2014 were identified in the Truven Health MarketScan Commercial administrative claims database...
February 1, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29143483/the-impact-of-mental-health-comorbidities-on-adherence-to-buprenorphine-a-claims-based-analysis
#7
Megan Litz, Douglas Leslie
BACKGROUND AND OBJECTIVES: Previous research has been inconclusive about whether opioid-dependent patients with psychiatric comorbidities have shorter treatment retention and higher relapse rates. This study aims to evaluate the impact of mental health comorbidities on adherence to buprenorphine using a large, national health insurance claims data base. METHODS: We used MarketScan® data from 2012 to 2014 to perform this analysis. Inclusion criteria included all patients with an opioid use disorder-related ICD-9 code who had been prescribed buprenorphine (n = 2947)...
November 16, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/29141650/neuropsychological-function-is-improved-among-opioid-dependent-adults-who-adhere-to-opiate-agonist-treatment-with-buprenorphine-naloxone-a-preliminary-study
#8
Travis M Scott, Monica Rivera Mindt, Chinazo O Cunningham, Franchesca Arias, Kelly Coulehan, Aprille Mangalonzo, Pat Olsen, Julia H Arnsten
BACKGROUND: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. METHODS: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age = 45.2 years [SD = 8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence...
November 15, 2017: Substance Abuse Treatment, Prevention, and Policy
https://www.readbyqxmd.com/read/29096016/opioid-use-disorders-medication-assisted-treatment-and-the-role-of-the-laboratory
#9
Roger L Bertholf, Gary M Reisfield
Urine drug testing is an essential component in the evaluation and management of individuals with opioid use disorders, including those on buprenorphine or methadone maintenance therapies. Notwithstanding its centrality in adherence monitoring, studies have shown that clinicians have important knowledge deficiencies regarding the ordering and interpretation of drug tests. In this review, we discuss the scope and frequency of testing, the advantages and disadvantages of immunoassay- (presumptive) and liquid chromatograph-mass spectrometry- (definitive) based techniques, indications for definitive testing, medical necessity, and other considerations...
November 8, 2017: Laboratory Medicine
https://www.readbyqxmd.com/read/29068826/opioid-addiction-in-pregnancy-does-depression-negatively-impact-adherence-with-prenatal-care
#10
Lauren Hensley, Suela Sulo, Sarah Kozmic, Barbara V Parilla
OBJECTIVE: We aimed to evaluate whether depression in pregnancy in women with opioid dependency negatively impacts adherence with prenatal care. METHODS: This was a retrospective chart analysis of opioid-dependent pregnant women over a 6-year period at 2 large referral and tertiary care centers. The primary outcome was adherence with prenatal care based on the concurrent diagnosis of depression. Adherence was assessed by looking at the number of observed versus expected prenatal visits...
October 24, 2017: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/28829626/transitioning-from-methadone-to-buprenorphine-maintenance-in-management-of-opioid-use-disorder-during-pregnancy
#11
Shakevia Johnson, Peter R Martin
BACKGROUND: Opioid use disorder during pregnancy is a growing health concern. Methadone maintenance is the treatment of choice but emerging data indicate buprenorphine is a viable alternative. Due to costs and limited accessibility of methadone, pregnant women may require transition from methadone to buprenorphine for maintenance treatment. OBJECTIVES: To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy...
August 22, 2017: American Journal of Drug and Alcohol Abuse
https://www.readbyqxmd.com/read/28817294/heterogeneity-of-nonadherent-buprenorphine-patients-subgroup-characteristics-and-outcomes
#12
Charles Ruetsch, Joseph Tkacz, Vijay R Nadipelli, Brenna L Brady, Naoko Ronquest, Hyong Un, Joseph Volpicelli
OBJECTIVES: To examine patient characteristics and outcomes associated with nonadherence to buprenorphine and to identify specific patterns of nonadherent behavior. STUDY DESIGN: Cross-sectional, retrospective analysis of health claims data. METHODS: Aetna's administrative claims data were used to categorize incident opioid use disorder (OUD) patients based on buprenorphine medication possession ratio (MPR) into adherent (n = 172) and nonadherent (n = 305) groups...
June 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28799677/text-message-reminders-for-improving-patient-appointment-adherence-in-an-office-based-buprenorphine-program-a-feasibility-study
#13
Babak Tofighi, Frank Grazioli, Sewit Bereket, Ellie Grossman, Yindalon Aphinyanaphongs, Joshua David Lee
BACKGROUND AND OBJECTIVES: Missed visits are common in office-based buprenorphine treatment (OBOT). The feasibility of text message (TM) appointment reminders among OBOT patients is unknown. METHODS: This 6-month prospective cohort study provided TM reminders to OBOT program patients (N = 93). A feasibility survey was completed following delivery of TM reminders and at 6 months. RESULTS: Respondents reported that the reminders should be provided to all OBOT patients (100%) and helped them to adhere to their scheduled appointment (97%)...
August 11, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/28723256/quantitative-testing-of-buprenorphine-and-norbuprenorphine-to-identify-urine-sample-spiking-during-office-based-opioid-treatment
#14
Joji Suzuki, Jennifer Zinser, Mohammed Issa, Claudia Rodriguez
BACKGROUND: Patients may spike urine samples with buprenorphine during office-based opioid treatment to simulate adherence to prescribed buprenorphine, potentially to conceal diversion of medications. However, routine immunoassay screens do not detect instances of spiking, as these would simply result in a positive result. The aim of this study was to report on the experience of using quantitative urine testing for buprenorphine and norbuprenorphine to facilitate the identification of urine spiking...
July 19, 2017: Substance Abuse
https://www.readbyqxmd.com/read/28669739/an-evidence-based-recommendation-to-increase-the-dosing-frequency-of-buprenorphine-during-pregnancy
#15
Steve N Caritis, Jaime R Bastian, Hongfei Zhang, Hari Kalluri, Dennis English, Michael England, Stephanie Bobby, Raman Venkataramanan
BACKGROUND: Dose-adjusted plasma concentrations of buprenorphine are significantly decreased during pregnancy compared with the nonpregnant state. This observation suggests that pregnant women may need a higher dose of buprenorphine than nonpregnant individuals to maintain similar drug exposure (plasma concentrations over time after a dose). The current dosing recommendations for buprenorphine during pregnancy address the total daily dose of buprenorphine to be administered, but the frequency of dosing is not clearly addressed...
October 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28571505/buprenorphine-implants-in-medical-treatment-of-opioid-addiction
#16
REVIEW
Steven Chavoustie, Michael Frost, Ole Snyder, Joel Owen, Mona Darwish, Ryan Dammerman, Victoria Sanjurjo
Opioid use disorder is a chronic, relapsing disease that encompasses use of both prescription opioids and heroin and is associated with a high annual rate of overdose deaths. Medical treatment has proven more successful than placebo treatment or psychosocial intervention, and the partial µ-opioid receptor agonist and κ-opioid receptor antagonist buprenorphine is similar in efficacy to methadone while offering lower risk of respiratory depression. However, frequent dosing requirements and potential for misuse and drug diversion contribute to significant complications with treatment adherence for available formulations...
August 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28348732/probuphine%C3%A2-buprenorphine-implant-a-promising-candidate-in-opioid-dependence
#17
REVIEW
Preeti Barnwal, Saibal Das, Somnath Mondal, Anand Ramasamy, Tanay Maiti, Arunava Saha
Opioid dependence leads to physical dependence and addiction which finally results in profound medical, psychological and social dysfunction. One of the useful medications for opioid dependence is buprenorphine, the partial opioid agonist, which is used alone or in combination with naloxone. However, buprenorphine is the victim of its own success due to its illicit use and accidental poisoning in children. Also, buprenorphine typically requires daily self-administration and its effectiveness heavily depends on patient adherence...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28267837/opioid-agonist-treatment-for-patients-with-dependence-on-prescription-opioids
#18
Suzanne Nielsen, Briony Larance, Nicholas Lintzeris
Clinical Question: Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid agonist treatment associated with differences in efficacy compared with opioid taper or psychological treatments alone? Bottom Line: For patients who are dependent on prescription opioids, long-term maintenance of opioid agonists is associated with less prescription opioid use and better adherence to medication and psychological therapies for opioid dependence compared with opioid taper or psychological treatments alone...
March 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28162850/examination-of-the-hepatitis-c-virus-care-continuum-among-individuals-with-an-opioid-use-disorder-in-substance-use-treatment
#19
Jennifer L Brown, Nicole K Gause, Daniel Lewis, Theresa Winhusen
BACKGROUND: Hepatitis C Virus (HCV) risk is elevated for individuals with an opioid use disorder (OUD). Routine HCV testing is recommended for high-risk individuals, including those with an injection drug use history. HCV antibody testing addresses the first step in the HCV treatment care cascade, with uptake and completion of HCV treatment among individuals with chronic HCV as the optimal care cascade endpoint. The aim of this study was to characterize self-reported HCV treatment cascade outcomes among individuals with an OUD in outpatient medication assisted treatment (MAT)...
February 2, 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28068780/long-acting-injectable-naltrexone-induction-a-randomized-trial-of-outpatient-opioid-detoxification-with-naltrexone-versus-buprenorphine
#20
RANDOMIZED CONTROLLED TRIAL
Maria Sullivan, Adam Bisaga, Martina Pavlicova, C Jean Choi, Kaitlyn Mishlen, Kenneth M Carpenter, Frances R Levin, Elias Dakwar, John J Mariani, Edward V Nunes
OBJECTIVE: At present there is no established optimal approach for transitioning opioid-dependent adults to extended-release injection naltrexone (XR-naltrexone) while preventing relapse. The authors conducted a trial examining the efficacy of two methods of outpatient opioid detoxification for induction to XR-naltrexone. METHOD: Participants were 150 opioid-dependent adults randomly assigned 2:1 to one of two outpatient detoxification regimens, naltrexone-assisted detoxification or buprenorphine-assisted detoxification, followed by an injection of XR-naltrexone...
May 1, 2017: American Journal of Psychiatry
keyword
keyword
119232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"